The head of genetic-test maker 23andMe responded to an FDA warning letter in a blog post Tuesday night, acknowledging the company was behind schedule in addressing FDA concerns but defending the accuracy and value of the company's tests.
from WSJ.com: US Business http://online.wsj.com/article/SB10001424052702303332904579224093983156448.html?mod=pls_whats_news_us_business_f
via IFTTT
from WSJ.com: US Business http://online.wsj.com/article/SB10001424052702303332904579224093983156448.html?mod=pls_whats_news_us_business_f
via IFTTT
No comments:
Post a Comment